SynthesisFrontiers in cardiovascular medicine2026
Troponin for surveillance of immune checkpoint inhibitor-associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis, a rare complication with high morbidity and mortality. ICI-associated myocarditis often presents with nonspecific clinical features, making early recognition challenging. Cardiac troponin is a widely available biomarker of myocardial injury and is increasingly used in cardio-oncology surveillance pathways; however, its performance for identifying ICI-associated myocarditis and its prognostic value for subsequent cardiovascular outcomes remain incompletely defined. Objectives: To evaluate the performance of cardiac troponin in the surveillance and identification of ICI-associated myocarditis and to assess its prognostic value for major adverse cardiovascular events (MACE) and mortality. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. Medline (PubMed), Embase, Cochrane CENTRAL, and Scopus were searched from inception to October 2025 for diagnostic and prognostic studies evaluating troponin (I or T; conventional or high-sensitivity) in adults receiving ICIs. Random-effects models were used to pool effect estimates. Performance for identifying ICI-associated myocarditis was assessed using odds ratios (ORs), and prognostic associations were summarized using hazard ratios (HRs). Results: Across diagnostic studies, troponin elevation was associated with confirmed ICI-associated myocarditis (pooled log OR 4.14, 95% CI 2.80-5.48), with no significant between study heterogeneity. However, false-positive troponin elevations were common, resulting in modest positive predictive value despite high sensitivity. In prognostic analyses, elevated troponin levels were associated with an increased risk of MACE (pooled HR 6.14, 95% CI 3.61-10.45) and all-cause mortality (pooled HR 1.95, 95% CI 1.36-2.81). These associations were consistent across studies with varying designs, troponin assays, and outcome definitions. Conclusions: Troponin elevation in patients receiving ICIs is associated with ICI-related myocarditis and with increased risk of adverse cardiovascular outcomes and mortality, supporting its role as an accessible biomarker for early clinical evaluation, surveillance, and risk stratification. However, because false-positive elevations are common and diagnostic performance varies by assay type, threshold, and timing, troponin should not be interpreted as a standalone diagnostic test. Prospective studies are needed to define optimal troponin-guided surveillance strategies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251176007 identifier CRD420251176007.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.